Engimmune Therapeutics raises USD 16.7 million in seed financing co-led by Pureos Bioventures and Novo Holdings
Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr Søren Mouritsen. The company is a spinout from Sai Reddy’s research group at the Department of Biosystems Science and Engineering (D- BSSE) of ETH Zurich, located in Basel.
Engimmune developed a suite of platform technologies based on genome editing, deep sequencing and high- throughput functional screening, which enables the engineering of synthetic TCRs that are highly potent and specific to a tumor target. Thus paving the way to more effective and safer TCR-T cell and soluble TCR therapeutics. Their first products target oncology indications but the platform has the potential to also address autoimmune diseases in the future.
In raising this seed financing, Engimmune will now be able to advance the preclinical development of its lead ENG-001, a potent TCR therapeutics for melanoma and other solid cancers, further expand the research team in Switzerland and strengthen the intellectual property.
BaseLaunch has supported Engimmune from early 2021 through its inception and now closing of the seed financing. Thanks to the quality of their scientific research and the commitment of the team, Engimmune was able to make great progress in a very short period of time. This led to the completion of a USD 16.7M seed financing, co-led by Pureos Bioventures and Novo Holdings.
According to Sai Reddy “BaseLaunch has been instrumental to the success of Engimmune, by supporting us even prior to our incorporation and through to the current financing”. We are proud of this extraordinary outcome and congratulate the whole team for reaching this important milestone!